| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.25292 |
| P698 | PubMed publication ID | 23436720 |
| P50 | author | Timothy M. Dall | Q39781094 |
| P2093 | author name string | Anjali Jain | |
| Michael V Storm | |||
| Stacey L Kowal | |||
| Ritashree Chakrabarti | |||
| P2860 | cites work | Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. | Q40273125 |
| Burden of illness in Parkinson's disease. | Q50764766 | ||
| Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. | Q50770517 | ||
| The health burdens of Parkinson's disease. | Q50884327 | ||
| Economic burden and quality of life impairment increase with severity of PD. | Q53397739 | ||
| How common are the "common" neurologic disorders? | Q22306182 | ||
| Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. | Q33859573 | ||
| Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity | Q34201593 | ||
| Neuroprotection trials in Parkinson's disease: systematic review | Q34913056 | ||
| The relative health related quality of life of veterans with Parkinson's disease. | Q35471560 | ||
| A review of the health-related quality of life and economic impact of Parkinson's disease | Q36613851 | ||
| Predictors of survival in patients with Parkinson disease | Q36690717 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 311-318 | |
| P577 | publication date | 2013-02-21 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | The current and projected economic burden of Parkinson's disease in the United States | |
| P478 | volume | 28 |
| Q50329951 | A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders |
| Q38697121 | A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement |
| Q58598324 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein |
| Q92275882 | A Systematic Review on the Cognitive Benefits and Neurophysiological Correlates of Exergaming in Healthy Older Adults |
| Q33739875 | A randomized trial of individual versus group-format exercise and self-management in individuals with Parkinson's disease and comorbid depression. |
| Q36172557 | A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease |
| Q48172426 | Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease. |
| Q35811453 | An Aminopropyl Carbazole Derivative Induces Neurogenesis by Increasing Final Cell Division in Neural Stem Cells |
| Q64864138 | An early diagnosis is not the same as a timely diagnosis of Parkinson's disease |
| Q64114559 | An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele |
| Q34800195 | An overview on the correlation of neurological disorders with cardiovascular disease |
| Q38269292 | An update on the use of botulinum toxin therapy in Parkinson's disease |
| Q90118142 | Anemia and the risk of Parkinson's disease in Korean older adults: A nationwide population-based study |
| Q90181023 | Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation |
| Q64122136 | Assessing Retinal Structure in Patients with Parkinson's Disease |
| Q36653647 | Association Between Tuberculosis and Parkinson Disease: A Nationwide, Population-Based Cohort Study |
| Q53106370 | Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea. |
| Q92151469 | Association of periodic limb movements during sleep and Parkinson disease: A retrospective clinical study |
| Q40220255 | Base excision repair variants and pesticide exposure increase Parkinson's disease risk |
| Q38700215 | Beyond muscles: The untapped potential of creatine |
| Q38935901 | Biological functions of selenium and its potential influence on Parkinson's disease |
| Q54439618 | Bridging the credibility gap in cost effectiveness analysis. |
| Q39624181 | Care Received by Elderly US Stroke Survivors May Be Underestimated |
| Q46420652 | Cerium oxide nanoparticles: a 'radical' approach to neurodegenerative disease treatment |
| Q26776237 | Chronic, intermittent convection-enhanced delivery devices |
| Q39179797 | Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care |
| Q38402094 | Cognition and Depression Following Deep Brain Stimulation of the Subthalamic Nucleus and Globus Pallidus Pars Internus in Parkinson's Disease: A Meta-Analysis |
| Q60950136 | Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years |
| Q48091456 | Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible? |
| Q38293054 | Combining cell transplants or gene therapy with deep brain stimulation for Parkinson's disease |
| Q92968669 | Comorbid Depression and Psychosis in Parkinson's Disease: A Report of 62,783 Hospitalizations in the United States |
| Q47765302 | Comparative Patient Satisfaction and Feasibility of a Pilot Parkinson's Disease Enrichment Program. |
| Q61453935 | Comparing Balance Performance on Force Platform Measures in Individuals with Parkinson's Disease and Healthy Adults |
| Q89735586 | Comparison Of Methods To Estimate Disease-Related Cost And Healthcare Resource Utilization For Autoimmune Diseases In Administrative Claims Databases |
| Q30252096 | Constipation preceding Parkinson's disease: a systematic review and meta-analysis. |
| Q47727602 | Continuation of full time employment as an inhibiting factor in Parkinson's disease symptoms. |
| Q38239051 | Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: a systematic review and meta-analysis |
| Q50953428 | Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. |
| Q34714560 | Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease |
| Q37703440 | Cost of Living with Parkinson's Disease over 12 Months in Australia: A Prospective Cohort Study. |
| Q48065494 | Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites |
| Q97527080 | Current and projected future economic burden of Parkinson's disease in the U.S. |
| Q26747575 | Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease |
| Q36391409 | Deep Brain Stimulation: Expanding Applications |
| Q26859169 | Deep brain stimulation for disorders of memory and cognition |
| Q30585845 | Deep brain stimulation for movement disorders |
| Q93018319 | Dementia-Related Functional Disability in Moderate to Advanced Parkinson's Disease: Assessment Using the World Health Organization Disability Assessment Schedule 2.0. |
| Q35124368 | Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease? |
| Q61810290 | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| Q64864697 | Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications |
| Q90679732 | Drug Repurposing in Parkinson's Disease |
| Q36018225 | Dynamic High-Cadence Cycling Improves Motor Symptoms in Parkinson's Disease |
| Q47655102 | Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in C. elegans Models of Parkinson's Disease. |
| Q38659681 | Economic Burden Analysis of Parkinson's Disease Patients in China |
| Q64767246 | Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review |
| Q35911113 | Economic Evaluation of a Tai Ji Quan Intervention to Reduce Falls in People With Parkinson Disease, Oregon, 2008-2011. |
| Q30407589 | Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial |
| Q64769001 | Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial |
| Q33648828 | Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design |
| Q58119943 | Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson's disease: a pilot randomized controlled trial |
| Q54099574 | Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis. |
| Q91495371 | Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease |
| Q38881221 | Epigenetic regulation in Parkinson's disease |
| Q64787879 | Estimated Residential Exposure to Agricultural Chemicals and Premature Mortality by Parkinson's Disease in Washington State |
| Q38618871 | Estimating the direct and indirect costs associated with Parkinson's disease. |
| Q38665765 | Estimation of genetic risk function with covariates in the presence of missing genotypes |
| Q64923612 | Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. |
| Q39002287 | Fall-related hospitalization in people with Parkinson's disease. |
| Q55040436 | Familial aggregation of Parkinson's disease and coaggregation with neuropsychiatric diseases: a population-based cohort study. |
| Q37664213 | First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers |
| Q39712008 | Functional Status of Elderly Nursing Home Residents With Parkinson's Disease. |
| Q37265697 | Gender differences in the adverse events' profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis. |
| Q58708254 | Genetic Modulation at the Neural Microelectrode Interface: Methods and Applications |
| Q90442587 | Gut Microbiota in Neurological Disorders |
| Q92809504 | Health Care Costs and Savings Associated with Increased Dairy Consumption among Adults in the United States |
| Q31172400 | Healthcare Data Analytics for Parkinson's Disease Patients: A Study of Hospital Cost and Utilization in the United States |
| Q91726969 | Healthcare Utilization and Costs for Patients With Parkinson's Disease After Deep Brain Stimulation |
| Q59341144 | Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials |
| Q33827945 | High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast |
| Q64071619 | High-Cadence Cycling Promotes Sustained Improvement in Bradykinesia, Rigidity, and Mobility in Individuals with Mild-Moderate Parkinson's Disease |
| Q28079187 | Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease |
| Q45776139 | Impact of Depression on Hospitalization and Related Outcomes for Parkinson's Disease Patients: A Nationwide Inpatient Sample-Based Retrospective Study |
| Q38256380 | Impaired intracellular trafficking defines early Parkinson's disease |
| Q90583875 | In Vitro and in Silico Human Monoamine Oxidase Inhibitory Potential of Anthraquinones, Naphthopyrones, and Naphthalenic Lactones from Cassia obtusifolia Linn Seeds |
| Q55244656 | Increasing Interest of Mass Communication Media and the General Public in the Distribution of Tweets About Mental Disorders: Observational Study. |
| Q104134116 | Informant-Reported Cognitive Decline is Associated with Objective Cognitive Performance in Parkinson's Disease |
| Q58780873 | Integrated Analysis Reveals Altered Lipid and Glucose Metabolism and Identifies NOTCH2 as a Biomarker for Parkinson's Disease Related Depression |
| Q47101523 | Inventory of real world data sources in Parkinson's disease |
| Q91977645 | Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales |
| Q64769176 | LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10 |
| Q61449887 | Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson's Disease |
| Q92702694 | Longitudinal assessment of falls in patients with Parkinson's disease using inertial sensors and the Timed Up and Go test |
| Q59545301 | Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease |
| Q46273780 | Mitochondria-targeted antioxidant therapy with MitoQ ameliorates aortic stiffening in old mice |
| Q53417465 | Motor Subtypes of Parkinson's Disease Can Be Identified by Frequency Component of Postural Stability. |
| Q37589114 | NADPH oxidase in brain injury and neurodegenerative disorders |
| Q38275050 | Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance |
| Q37081102 | National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. |
| Q92859477 | Neural Recording and Modulation Technologies |
| Q89962932 | Neurophysiological Biomarkers of Parkinson's Disease |
| Q48061121 | Nutrition and Lifestyle Intervention on Mood and Neurological Disorders |
| Q94595252 | Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraph® |
| Q41158597 | Obstructive sleep apnea and risk of Parkinson's disease: a population-based cohort study |
| Q50105039 | Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders |
| Q39350609 | Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. |
| Q64251191 | Palmitate and Stearate are Increased in the Plasma in a 6-OHDA Model of Parkinson's Disease |
| Q96136909 | Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls |
| Q30381816 | Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. |
| Q47720092 | Parkinson disease with and without Dementia: A prevalence study and future projections |
| Q39310359 | Parkinson patients as partners in care |
| Q55715822 | Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. |
| Q39075112 | Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta. |
| Q52149136 | Parkinson's disease: From human genetics to clinical trials. |
| Q47614598 | ParkinsonNet: A Low-Cost Health Care Innovation With A Systems Approach From The Netherlands |
| Q38218281 | Parkinsonism and inborn errors of metabolism. |
| Q57790000 | Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches |
| Q35675060 | Person-Centered Care in the Home Setting for Parkinson's Disease: Operation House Call Quality of Care Pilot Study. |
| Q38339672 | Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity |
| Q94552422 | Plastrum Testudinis Extracts Promote NSC Differentiation into Dopaminergic Neuron by Regulating the Interaction of TET1 and FoxA2 |
| Q90256243 | Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease |
| Q90194740 | Postural Instability in Parkinson's Disease: A Review |
| Q26779516 | Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations |
| Q60930169 | Predictors of mobility domain of health-related quality of life after rehabilitation in Parkinson's disease: a pilot study |
| Q38826867 | Preferences and concerns for care needs in advanced Parkinson's disease: a qualitative study of couples |
| Q40422920 | Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline |
| Q47123908 | Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference |
| Q48004994 | Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance |
| Q38673735 | Projection of the prevalence of Parkinson's disease in the coming decades: Revisited |
| Q38761409 | Proteomic studies associated with Parkinson's disease. |
| Q94602302 | Psychosocial Adjustment of In-Home Caregivers of Family Members with Dementia and Parkinson's Disease: A Comparative Study |
| Q37008911 | Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary |
| Q60045516 | Reduced workforce participation 5 years prior to first Parkinson's disease sick-leave |
| Q55090022 | Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. |
| Q39864198 | Relational Issues Within Couples Coping With Parkinson's Disease: Implications and Ideas for Family-Focused Care |
| Q57492325 | Reliability of a Novel Video-Based Method for Assessing Age-Related Changes in Upper Limb Kinematics |
| Q89912027 | Research-based Updates in Swallowing and Communication Dysfunction in Parkinson Disease: Implications for Evaluation and Management |
| Q38785075 | Retrograde Axonal Degeneration in Parkinson Disease |
| Q94464029 | Rhodopsin: A Potential Biomarker for Neurodegenerative Diseases |
| Q47194743 | Role of Estrogen and Other Sex Hormones in Brain Aging. Neuroprotection and DNA Repair |
| Q38242043 | Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome |
| Q38186171 | SIRT1 in neurodevelopment and brain senescence |
| Q37062741 | Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk |
| Q30375563 | Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. |
| Q26744569 | Sex and Gender Differences in Central Nervous System-Related Disorders |
| Q47652448 | Sex differences in sleep apnea and comorbid neurodegenerative diseases. |
| Q37629567 | Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females |
| Q39203461 | Short-Term Adverse Outcomes After Deep Brain Stimulation Treatment in Patients with Parkinson Disease |
| Q40670425 | Simple Test of Manual Dexterity Can Help to Identify Persons at High Risk for Neurodegenerative Diseases in the Community |
| Q45201060 | Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress |
| Q89718262 | Stem Cell Transplantation and Physical Exercise in Parkinson's Disease, a Literature Review of Human and Animal Studies |
| Q90956184 | Stem-Cell Research of Parkinson Disease: Bibliometric Analysis of Research Productivity from 1999 to 2018 |
| Q58697995 | Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols |
| Q37710224 | Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease |
| Q27007413 | Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic |
| Q60950148 | The Emerging Evidence of the Parkinson Pandemic |
| Q92201394 | The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository |
| Q36223734 | The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review |
| Q88947004 | The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes |
| Q40335775 | The burden of neurological disease in the United States: A summary report and call to action |
| Q38449574 | The economic impact of amyotrophic lateral sclerosis: a systematic review. |
| Q44225126 | The effects of yoga versus stretching and resistance training exercises on psychological distress for people with mild-to-moderate Parkinson's disease: study prxotocol for a randomized controlled trial. |
| Q64786607 | The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States |
| Q43409823 | The murky path to drug discovery in ALS becomes clearer |
| Q58566132 | The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease |
| Q35145894 | The role of astrocyte mitochondria in differential regional susceptibility to environmental neurotoxicants: tools for understanding neurodegeneration |
| Q28069664 | The role of leptin in central nervous system diseases |
| Q39387480 | Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease |
| Q41524210 | Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice |
| Q52371823 | Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication. |
| Q91246297 | Time Trends of the Incidence, Prevalence, and Mortality of Parkinsonism |
| Q27693350 | Time to change the blind men and the elephant approach to Parkinson disease? |
| Q37651160 | Trends in antiparkinsonian medication use in new zealand: 1995-2011. |
| Q39759171 | Trends in the Incidence of Parkinson Disease in the General Population: The Rotterdam Study |
| Q34625918 | Unbiased approaches to biomarker discovery in neurodegenerative diseases |
| Q48092663 | Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders. |
| Q37523363 | Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease |
| Q89884211 | Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression |
| Q91866682 | Using Drosophila as a platform for drug discovery from natural products in Parkinson's disease |
| Q39855664 | Workforce unavailability in Parkinson's disease. |
| Q33763808 | Wound research funding from alternative sources of federal funds in 2012. |
Search more.